Investor Presentaiton
Strong track record
Unique model
Large moat
Significant opportunity
Compounding growth
Drivers of growth are diversified across the portfolio
ROYALTY PHARMA
Established growth portfolio
Recently launched products
Development-stage pipeline
Future royalty acquisitions
~$10-12bn opportunity
to deploy value-creating
capital over next 5 years
~25 approved products
of which 12 were
blockbusters in 2021
9 recent launches of which
6 are expected to be
blockbusters in 2025(1)
10 development-stage
therapies
Potential for all to launch
by end of 2025
Diverse mix of marquee and recently launched products, exciting development-stage therapies and future royalty acquisitions
ROYALTY PHARMA 1. Based on Visible Alpha consensus estimates.
17View entire presentation